AGIOS PHARMACEUTICALS, INC.

AGIO

AGIOS PHARMACEUTICALS, INC.

AGIO

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-04-02Shares Purchased (TTM):0Shares Sold (TTM):143,676

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:59,159,046Shares Outstanding:58,782,241Institutional Ownership Pct.:100.64%

Earnings Market Reaction:

Filing Date:2026-04-29Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

AGIOS PHARMACEUTICALS, INC. (AGIO) — SEC Financial Statements & Analysis

AGIOS PHARMACEUTICALS, INC. (AGIO) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	114	89	93	81	79	76	254	85	119	88	64	85
Available For Sale Securities Debt Securities Curr…	623	765	860	858	814	817	751	485	479	689	583	618
Contract With Customer Asset Net Current	16	11	5	5	3	4	3	4	3	3	1	2
Inventory Net	35	33	32	31	30	28	26	24	23	19	17	16
Prepaid Expense And Other Assets Current	47	44	43	45	42	40	40	35	39	35	38	37
Assets Current	835	942	1,033	1,019	969	966	1,074	632	664	834	704	757
Available For Sale Securities Debt Securities Nonc…	308	310	304	400	531	638	656	75	116	29	225	244
Operating Lease Right Of Use Asset	27	30	34	37	40	43	46	49	52	54	57	60
Property Plant And Equipment Net	11	11	11	11	11	12	12	13	14	15	17	20
Other Assets Noncurrent	4	4	4	4	5	5	4	4	4	4	4	4
Assets	1,185	1,297	1,386	1,471	1,556	1,663	1,792	773	850	937	1,007	1,085
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	14	18	20	18	14	17	17	10	11	10	13	12
Accrued Liabilities Current	26	45	37	35	21	47	33	37	25	43	30	29
Taxes Payable Current	-	0	0	0	1	1	53	-	-	0	-	-
Operating Lease Liability Current	19	18	18	18	17	17	16	16	15	15	15	14
Liabilities Current	59	82	75	70	52	81	119	63	52	68	58	55
Operating Lease Liability Noncurrent	17	22	27	31	36	40	45	49	53	57	61	65
Other Liabilities Noncurrent	0	0	0	0	1	1	1	1	1	1	1	1
Liabilities	76	104	101	102	89	122	165	113	106	126	120	121
Stockholders Equity
Preferred Stock Value Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	2,573	2,555	2,538	2,522	2,507	2,494	2,478	2,464	2,452	2,437	2,422	2,411
Accumulated Other Comprehensive Income Loss Availa…	-0	2	2	1	0	-2	3	-1	-1	-0	-6	-9
Retained Earnings Accumulated Deficit	-661	-562	-454	-350	-238	-149	-52	-1,000	-904	-823	-727	-635
Treasury Stock Value	-802	-802	-802	-802	-802	-802	-802	-802	-802	-802	-802	-802
Stockholders Equity	1,109	1,193	1,284	1,370	1,467	1,541	1,627	661	744	811	887	964
Liabilities And Stockholders Equity	1,185	1,297	1,386	1,471	1,556	1,663	1,792	773	850	937	1,007	1,085
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	25	25	25	25	25	25	25	25	25	25	25	25
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	125	125	125	125	125	125	125	125	125	125	125	125
Common Stock Shares Issued	76	75	74	74	74	73	73	73	73	72	72	72
Shares Outstanding	59	58	58	58	58	57	57	57	57	56	56	56
Treasury Stock Common Shares	16	16	16	16	16	16	16	16	16	16	16	16

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	0.32%	21.78%	-	-	-	-	-	-	-	-	-	-
2025	-3.68%	11.22%	29.28%	4.25%	1.29%	13.73%	-41.55%	-43.35%	-37.03%	-2.14%	25.40%	0.32%
2024	-8.91%	30.77%	34.79%	3.87%	4.61%	2.25%	25.32%	-20.28%	-27.03%	-2.76%	-22.64%	-9.61%
2023	4.87%	8.85%	11.78%	3.97%	-5.44%	-17.58%	6.33%	14.00%	3.48%	16.75%	2.80%	28.88%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	14.19	11.46	13.82	14.48	18.50	11.90	8.99	10.09	12.84	12.27	12.06	13.73
Quick Ratio	12.80	10.52	12.81	13.41	17.12	11.06	8.44	9.16	11.64	11.47	11.10	12.78
Working Capital	776.00M	859.85M	958.35M	949.05M	916.25M	884.44M	954.74M	569.49M	611.94M	765.88M	645.93M	702.10M
Leverage & Debt
Debt to Equity	0.07	0.09	0.08	0.07	0.06	0.08	0.10	0.17	0.14	0.16	0.14	0.13
Interest Coverage TTM	-9.31	-8.37	-7.67	-7.48	-7.96	-8.85	-10.52	-11.91	-11.51	-11.74	-11.41	-12.86
Debt Ratio	0.06	0.08	0.07	0.07	0.06	0.07	0.09	0.15	0.12	0.13	0.12	0.11
Efficiency & Turnover
Asset Turnover TTM	0.05	0.04	0.03	0.04	0.03	0.03	0.02	0.03	0.03	0.02	0.02	0.02
Per Share Metrics
Diluted EPS TTM	-7.19	-7.12	-6.90	11.22	11.59	11.64	11.54	-6.42	-6.25	-6.33	-3.94	-3.78
Free Cash Flow Per Share TTM	-6.54	-6.51	-7.12	-7.06	-7.03	-6.89	-5.80	-5.41	-5.35	-5.34	-5.21	-5.40
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	90.04%	88.26%	87.22%	88.18%	87.52%	88.59%	89.38%	89.33%	89.95%	89.26%	88.73%	87.13%
Operating Profit Margin TTM	-719.97%	-873.87%	-1,061.80%	-1,129.13%	-1,188.86%	-1,166.47%	-1,238.10%	-1,293.88%	-1,336.41%	-1,459.52%	-1,599.59%	-1,859.21%
Net Profit Margin TTM	-639.84%	-764.01%	-895.86%	1,590.42%	1,798.26%	1,845.92%	2,051.38%	-1,165.69%	-1,199.26%	-1,312.63%	-913.95%	-1,042.56%
Growth Metrics
Net Revenue Growth (1Y)	78.34%	48.03%	36.26%	30.57%	25.96%	36.07%	36.79%	55.39%	54.61%	88.36%	141.99%	214.11%
Net Income Growth (1Y)	-163.46%	-161.27%	-159.51%	-278.14%	-288.87%	-291.35%	-407.03%	73.74%	61.72%	51.89%	-39.49%	-43.23%
EPS Growth (1Y)	-162.03%	-160.04%	-158.28%	-274.66%	-285.33%	-287.46%	-400.91%	70.07%	58.51%	49.54%	-40.53%	-44.05%
Valuation Metrics
P/E TTM	-4.71	-3.82	-5.82	2.96	2.53	2.77	3.75	-6.71	-4.68	-3.52	-6.29	-7.50
P/B	1.79	1.32	1.82	1.41	1.15	1.21	1.56	3.71	2.22	1.53	1.56	1.63
P/S TTM	30.11	29.21	52.10	47.14	45.46	51.15	76.96	78.24	56.07	46.21	57.48	78.16
Market Cap	1.99B	1.58B	2.33B	1.93B	1.68B	1.87B	2.53B	2.45B	1.65B	1.24B	1.38B	1.57B
Enterprise Value	1.88B	1.49B	2.24B	1.85B	1.60B	1.79B	2.28B	2.36B	1.53B	1.15B	1.32B	1.49B
Calculated Values
Free Cash Flow TTM	-384.73M	-377.29M	-414.09M	-409.03M	-403.77M	-391.53M	-330.11M	-307.49M	-301.49M	-297.07M	-290.62M	-300.00M
Net Debt	-113.60M	-89.13M	-92.71M	-80.87M	-78.96M	-76.25M	-253.73M	-84.52M	-118.76M	-88.21M	-64.33M	-84.75M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-02Sale

Owner: Jones, Cecilia

Title: Chief Financial Officer

Shares: 3,141

Price/Share: $34.71

Value: $109,024.11

Shares Owned: 54,998

Relationship: Officer

Ownership: Direct

2026-04-02Sale

Owner: Burns, James William

Title: Chief Legal Officer

Shares: 3,280

Price/Share: $34.71

Value: $113,848.80

Shares Owned: 49,306

Relationship: Officer

Ownership: Direct

2026-04-02Sale

Owner: Viswanadhan, Krishnan

Title: Chief Corp Dev & Strategy

Shares: 2,959

Price/Share: $34.71

Value: $102,706.89

Shares Owned: 10,282

Relationship: Officer

Ownership: Direct

2026-04-02Sale

Owner: Goff, Brian

Title: Chief Executive Officer

Shares: 19,068

Price/Share: $34.71

Value: $661,850.28

Shares Owned: 177,604

Relationship: Director,Officer

Ownership: Direct

2026-04-02Sale

Owner: Milanova, Tsveta

Title: Chief Commercial Officer

Shares: 3,262

Price/Share: $34.71

Value: $113,224.02

Shares Owned: 46,829

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-02	Jones, Cecilia	Officer	Chief Financial Officer	Direct	Sale	3,141	34.71	$109,024.11	54,998	4
2026-04-02	Burns, James William	Officer	Chief Legal Officer	Direct	Sale	3,280	34.71	$113,848.80	49,306	4
2026-04-02	Viswanadhan, Krishnan	Officer	Chief Corp Dev & Strategy	Direct	Sale	2,959	34.71	$102,706.89	10,282	4
2026-04-02	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	19,068	34.71	$661,850.28	177,604	4
2026-04-02	Milanova, Tsveta	Officer	Chief Commercial Officer	Direct	Sale	3,262	34.71	$113,224.02	46,829	4
2026-04-02	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	2,940	34.71	$102,047.40	80,277	4
2026-03-05	Viswanadhan, Krishnan	Officer	Chief Corp Dev & Strategy	Direct	Sale	2,959	27.80	$82,260.20	5,141	4
2026-03-03	Washburn, Theodore James …	Officer	Principal Accounting Officer	Direct	Sale	5,272	28.88	$152,255.36	868	4
2026-03-02	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	4,055	28.96	$117,432.80	67,608	4
2026-03-02	Burns, James William	Officer	Chief Legal Officer	Direct	Sale	5,218	28.96	$151,113.28	34,531	4
2026-03-02	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	18,055	28.96	$522,872.80	147,733	4
2026-03-02	Jones, Cecilia	Officer	Chief Financial Officer	Direct	Sale	5,035	28.96	$145,813.60	38,800	4
2026-03-02	Milanova, Tsveta	Officer	Chief Commercial Officer	Direct	Sale	2,868	28.96	$83,057.28	38,778	4
2026-03-02	Washburn, Theodore James …	Officer	Principal Accounting Officer	Direct	Sale	2,223	28.96	$64,378.08	2,595	4
2026-01-05	Milanova, Tsveta	Officer	Chief Commercial Officer	Direct	Sale	2,872	27.02	$77,601.44	34,793	4
2025-12-30	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	18,703	27.09	$506,664.27	136,583	4
2025-12-30	Jones, Cecilia	Officer	Chief Financial Officer	Direct	Sale	2,932	27.09	$79,427.88	37,394	4
2025-12-30	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	2,932	27.09	$79,427.88	64,795	4
2025-12-30	Milanova, Tsveta	Officer	Chief Commercial Officer	Direct	Sale	2,932	27.09	$79,427.88	29,190	4
2025-12-30	Burns, James William	Officer	Chief Legal Officer	Direct	Sale	2,932	27.09	$79,427.88	31,718	4
2025-11-12	Scadden, David	Director	-	Direct	Sale	200	43.84	$8,768.00	17,603	4
2025-11-11	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	2,454	43.78	$107,436.12	61,727	4
2025-10-30	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	200	43.81	$8,762.00	61,727	4
2025-10-27	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	3,302	43.92	$145,023.84	61,727	4
2025-10-08	Scadden, David	Director	-	Direct	Sale	200	41.00	$8,200.00	17,603	4
2025-09-30	Scadden, David	Director	-	Direct	Sale	200	40.00	$8,000.00	17,603	4
2025-09-26	Jones, Cecilia	Officer	Chief Financial Officer	Direct	Sale	3,651	36.77	$134,247.27	33,870	4
2025-09-05	Washburn, Theodore James …	Officer	Principal Accounting Officer	Direct	Sale	8,546	36.87	$315,091.02	868	4
2025-08-27	Scadden, David	Director	-	Direct	Sale	200	40.00	$8,000.00	17,603	4
2025-08-08	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	11,085	36.67	$406,486.95	123,528	4
2025-07-10	Scadden, David	Director	-	Direct	Sale	1,400	40.00	$56,000.00	17,603	4
2025-07-09	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	11,914	38.34	$456,782.76	61,271	4
2025-07-01	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	4,091	34.17	$139,789.47	61,271	4
2025-06-24	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	2,909	33.54	$97,567.86	56,988	4
2025-06-24	Jones, Cecilia	Officer	Chief Financial Officer	Direct	Sale	1,780	33.54	$59,701.20	30,049	4
2025-06-24	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	18,700	33.54	$627,198.00	105,401	4
2025-06-24	Milanova, Tsveta	Officer	Chief Commercial Officer	Direct	Sale	2,770	33.54	$92,905.80	26,122	4
2025-06-24	Burns, James William	Officer	Chief Legal Officer	Direct	Sale	2,799	33.54	$93,878.46	28,650	4
2025-04-10	Fouse, Jacqualyn A	Director	-	Direct	Sale	7,497	25.90	$194,172.30	149,220	4
2025-03-03	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	12,947	35.54	$460,136.38	83,139	4
2025-03-03	Washburn, Theodore James …	Officer	Principal Accounting Officer	Direct	Sale	1,655	35.54	$58,818.70	6,038	4
2025-03-03	Milanova, Tsveta	Officer	Chief Commercial Officer	Direct	Sale	1,681	35.54	$59,742.74	22,892	4
2025-03-03	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	4,005	35.54	$142,337.70	47,098	4
2025-03-03	Burns, James William	Officer	Chief Legal Officer	Direct	Sale	4,005	35.54	$142,337.70	18,650	4
2025-03-03	Jones, Cecilia	Officer	Chief Financial Officer	Direct	Sale	2,275	35.54	$80,853.50	21,843	4
2025-02-05	Washburn, Theodore James …	Officer	Principal Accounting Officer	Direct	Sale	2,272	34.39	$78,134.08	5,437	4
2025-01-06	Milanova, Tsveta	Officer	Chief Commercial Officer	Direct	Sale	2,804	32.18	$90,232.72	18,906	4
2024-12-11	Scadden, David	Director	-	Direct	Sale	200	46.28	$9,256.00	15,483	4
2024-11-08	Washburn, Theodore James …	Officer	Principal Accounting Officer	Direct	Sale	772	56.09	$43,301.48	813	4
2024-11-08	Ballal, Rahul D.	Director	-	Direct	Sale	10,000	58.34	$583,400.00	7,992	4
2024-11-07	Burns, James William	Officer	Chief Legal Officer	Direct	Sale	21,752	52.28	$1,137,194.56	15,700	4
2024-09-26	Jones, Cecilia	Officer	Chief Financial Officer	Direct	Sale	2,542	49.03	$124,634.26	20,158	4
2024-08-08	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	11,091	42.75	$474,140.25	78,792	4
2024-07-01	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	3,705	43.85	$162,464.25	43,736	4
2024-06-05	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	12,115	48.84	$591,696.60	67,192	4
2024-06-03	Washburn, Theodore James …	Officer	Principal Accounting Officer	Direct	Sale	1,362	44.39	$60,459.18	1,524	4
2024-04-10	Fouse, Jacqualyn A	Director	-	Direct	Sale	7,791	27.55	$214,642.05	137,396	4
2024-03-07	Foster-Cheek, Kaye I	Director	-	Direct	Sale	1,285	31.62	$40,631.70	5,524	4
2024-03-06	Foster-Cheek, Kaye I	Director	-	Direct	Sale	4,415	31.99	$141,235.85	6,809	4
2024-03-05	Washburn, Theodore James …	Officer	Principal Accounting Officer	Direct	Sale	1,913	31.75	$60,737.75	2,886	4
2024-03-05	Jones, Cecilia	Officer	Chief Financial Officer	Direct	Sale	672	32.57	$21,887.04	14,840	4
2024-03-05	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	2,642	32.57	$86,049.94	36,415	4
2024-03-05	Burns, James William	Officer	Chief Legal Officer	Direct	Sale	2,642	32.57	$86,049.94	34,518	4
2024-03-05	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	4,156	32.57	$135,360.92	53,780	4
2024-02-27	Schenkein, David P	Director	-	Direct	Sale	69,329	34.25	$2,374,518.25	122,854	4
2024-02-26	Schenkein, David P	Director	-	Direct	Sale	20,411	33.19	$677,441.09	122,854	4
2024-02-20	Washburn, Theodore James …	Officer	Principal Accounting Officer	Direct	Sale	504	26.63	$13,421.52	2,741	4
2024-02-14	Burns, James William	Officer	Chief Legal Officer	Direct	Sale	545	25.14	$13,701.30	31,666	4
2024-02-14	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	642	25.14	$16,139.88	33,431	4
2024-02-14	Washburn, Theodore James …	Officer	Principal Accounting Officer	Direct	Sale	273	25.14	$6,863.22	3,245	4
2024-01-24	Milanova, Tsveta	Officer	Chief Commercial Officer	Direct	Sale	1,618	21.64	$35,013.52	13,234	4
2024-01-24	Fouse, Jacqualyn A	Director	-	Direct	Sale	10,722	21.64	$232,024.08	129,253	4
2024-01-24	Jones, Cecilia	Officer	Chief Financial Officer	Direct	Sale	1,886	21.64	$40,813.04	13,069	4
2024-01-24	Burns, James William	Officer	Chief Legal Officer	Direct	Sale	1,708	21.64	$36,961.12	30,378	4
2024-01-24	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	1,708	21.64	$36,961.12	31,911	4
2024-01-24	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	7,635	21.64	$165,221.40	49,436	4
2024-01-09	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	1,789	22.99	$41,129.11	27,869	4
2024-01-09	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	12,066	22.99	$277,397.34	40,053	4
2024-01-09	Fouse, Jacqualyn A	Director	-	Direct	Sale	8,391	22.99	$192,909.09	116,075	4
2024-01-09	Burns, James William	Officer	Chief Legal Officer	Direct	Sale	1,163	22.99	$26,737.37	26,336	4
2024-01-05	Milanova, Tsveta	Officer	Chief Commercial Officer	Direct	Sale	2,902	22.32	$64,772.64	9,404	4
2023-09-28	Jones, Cecilia	Officer	Chief Financial Officer	Direct	Sale	2,179	24.79	$54,017.41	9,575	4
2023-08-17	Burns, James William	Officer	Chief Legal Officer	Direct	Sale	6,395	26.28	$168,060.60	23,890	4
2023-08-09	Foster-Cheek, Kaye I	Director	-	Direct	Sale	25,000	25.96	$649,000.00	11,524	4
2023-08-08	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	10,178	25.48	$259,335.44	26,592	4
2023-08-07	Washburn, Theodore James …	Officer	Principal Accounting Officer	Direct	Sale	2,918	25.39	$74,088.02	2,741	4
2023-08-01	Washburn, Theodore James …	Officer	Principal Accounting Officer	Direct	Sale	1,232	26.26	$32,352.32	5,659	4
2023-06-30	Goff, Brian	Director,Officer	Chief Executive Officer	Direct	Sale	11,449	28.36	$324,693.64	14,079	4
2023-06-30	Jones, Cecilia	Officer	Chief Financial Officer	Direct	Sale	1,597	28.36	$45,290.92	3,783	4
2023-06-30	Milanova, Tsveta	Officer	Chief Commercial Officer	Direct	Sale	1,618	28.36	$45,886.48	3,831	4
2023-06-30	Burns, James William	Officer	Chief Legal Officer	Direct	Sale	1,707	28.36	$48,410.52	30,285	4
2023-06-30	Fouse, Jacqualyn A	Director	-	Direct	Sale	10,718	28.36	$303,962.48	106,966	4
2023-06-30	Gheuens, Sarah	Officer	Chief Medical Officer	Direct	Sale	1,707	28.36	$48,410.52	24,159	4
2023-04-03	Schenkein, David P	Director	-	Direct	Sale	16,363	22.85	$373,894.55	117,879	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

100.64%

Inst. Shares: 59,159,046

Shares Outstanding: 58,782,241

2025-12-31

98.77%

Inst. Shares: 57,257,968

Shares Outstanding: 57,972,004

2025-09-30

102.87%

Inst. Shares: 59,808,936

Shares Outstanding: 58,139,277

2025-06-30

98.51%

Inst. Shares: 57,068,240

Shares Outstanding: 57,932,576

2025-03-31

96.31%

Inst. Shares: 55,340,256

Shares Outstanding: 57,459,195

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	59,159,046	58,782,241	100.64%
2025-12-31	57,257,968	57,972,004	98.77%
2025-09-30	59,808,936	58,139,277	102.87%
2025-06-30	57,068,240	57,932,576	98.51%
2025-03-31	55,340,256	57,459,195	96.31%
2024-12-31	54,912,803	56,807,415	96.66%
2024-09-30	52,461,692	56,939,403	92.14%
2024-06-30	50,800,497	56,802,546	89.43%
2024-03-31	54,270,892	56,383,475	96.25%
2023-12-31	53,550,233	55,651,487	96.22%
2023-09-30	53,182,014	55,803,663	95.30%
2023-06-30	52,912,413	55,604,330	95.16%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

AGIOS PHARMACEUTICALS, INC. (AGIO) — SEC Financial Statements & Analysis

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.